Hello,
The Sun pharmaceutical industries has reported that it has received approval from the Drugs Controller General of India (DCGI) to conduct clinical trials involving treatment of covid-19 patients with the drug named as Nafamostat Mesilate. The same drug has been approved in Japan for the treatment of acute symptoms of pancreatitis and disseminated intravascular coagulation (DIC).
The Sun pharmaceutical industries has reported that it has received approval from the Drugs Controller General of India (DCGI) to conduct clinical trials involving treatment of covid-19 patients with the drug named as Nafamostat Mesilate. The same drug has been approved in Japan for the treatment of acute symptoms of pancreatitis and disseminated intravascular coagulation (DIC).
According to Sun pharmaceuticals Nafamostat has shown promising data against SARS-COV2 virus in in-vitro studies conducted by three independent groups of scientists in Europe, Japan and South Korea.
Researchers from University of Tokyo and Leibniz (Germany) Institute of Primate Research reportedly have demonstrated Nafamostat, dosed in very low concentrations, suppresses a protein (TMPRSS2) that the covid-19 virus uses to enter the human lung cells. Additionally, Scientist with Institu Pasteur in south Korea reportedly compared the antiviral efficacy of Nefamostat and 24 other drugs against SARS-Cov2 in in-vitro studies in human lung epithelial derived cells, finding Nafamostat as most potent drug.
No comments:
Post a Comment